Rising Opportunities in API Manufacturing as Innovative Biologic Approvals Increase

Pharma Trends Rising Opportunities in API Manufacturing as Innovative Biologic Approvals Increase

19.05.2021Editor: Ahlam Rais

In 2020, the Food and Drug Administration (FDA) approved more biologic new molecular entities as compared to the previous years. In this background, the leading data and analytics company Global Data also found that the sponsors increased the outsourcing of these biologics’ active pharmaceutical ingredient (API) manufacturing.

Related Vendors

GlobalData

Pörner Ingenieurgesellschaft mbH

Maag Pump Systems AG

MG2 s.r.l.

Mega cap and large cap companies sponsored 52 % of FDA approvals of biologic NMEs in 2020: Global Data.
(Source: Global Data, Pharma Intelligence Center)

London/UK – The FDA approved more biologic new molecular entities (NMEs) in 2020 than in any other year in the previous decade, while at the same time, sponsors increased the outsourcing of these biologics’ API manufacturing. Mega cap and large cap companies sponsored 52 % of FDA approvals of biologic NMEs in 2020, says Global Data, a leading data and analytics company.

Adam Bradbury, Pharmsource Analyst at Global Data, comments: “As pipeline and marketed biologics increase in both complexity and number, most contract manufacturing organizations (CMOs) remain unable to manufacture biologic APIs to meet sponsor companies’ needs. CMOs can benefit from investing in capabilities and expertise to produce and handle sensitive biologics, as the marketed drugs landscape will become increasingly flooded with these in the coming years.”

The outsourcing of manufacturing of biologic (protein and peptide) NMEs has been increasing since 2017, while the outsourcing propensity for biologic APIs was higher than dose manufacturing during 2019–2020.

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

Bradbury continues: “API for biologics—protein and peptide, as well as advanced therapy medicinal products (ATMPs)—have become increasingly complex, and larger companies are leaning on the expertise of CMOs for API production.”

Among the biologics that received Covid-19 Emergency Use Approvals, API outsourcing was at an even higher level than for those biologics receiving full market approval, and Covid-19 vaccines in particular have been heavily outsourced due to scale or technical expertise difficulties.

Bradbury adds: “Unfortunately for CMOs, larger companies tend to invest in developing their own internal manufacturing capabilities to manufacture drugs rather than outsource production. However, they do frequently dual source to mitigate risk and for other strategic reasons.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47412389)